Bristol-Myers Squibb: all 2,184 studies

Page 20 of 22. Open to participants first (162), then studies with results posted, then the rest; newest registration first within each.

• Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin ResistanceCompletedNCT00699790Phase 2
• Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced MalignanciesCompletedNCT00697632Phase 1
• Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced CancerCompletedNCT00688415Phase 1
• BMS-741672 for Diabetic Neuropathic PainCompletedNCT00683423Phase 2
• Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced MalignanciesCompletedNCT00679133Phase 1
• Expanded Access for Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With LipodystrophyNo longer availableNCT00677313
• A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic CancerCompletedNCT00670189Phase 1
• NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or LymphomaCompletedNCT00667082Phase 1
• Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)TerminatedNCT00666497Phase 2
• A Single Ascending Dose Study of BMS-791325 in HCV Infected SubjectsCompletedNCT00664625Phase 1/2
• Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple MyelomaCompletedNCT00657488Phase 2/3
• A Study of MDX-1100 in Subjects With Active Ulcerative ColitisCompletedNCT00656890Phase 2
• Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer.CompletedNCT00656734Phase 1
• Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00651508Phase 2
• A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate CancerCompletedNCT00644488Phase 1
• Study of the Safety of MDX-1342 in Combination With Methotrexate in Patients With Rheumatoid ArthritisCompletedNCT00639834Phase 1
• ABI-009 Trial in Patients With Advanced Non-hematologic MalignanciesCompletedNCT00635284Phase 1
• Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's LymphomaCompletedNCT00634452Phase 1
• Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor TypesCompletedNCT00633789Phase 2
• Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced MalignanciesCompletedNCT00629473Phase 1
• Phase II, 2nd Line Melanoma - RAND MonotherapyCompletedNCT00612664Phase 2
• PoC in Rheumatoid Arthritis With MethotrexateCompletedNCT00605735Phase 2
• Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid TumorsCompletedNCT00605618Phase 1/2
• A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant DisordersStatus unknownNCT00596999
• Phase I/II Combination With Irinotecan- ErbituxCompletedNCT00594984Phase 1/2
• Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)CompletedNCT00593944Phase 1
• Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male SubjectsCompletedNCT00578916Phase 1
• Efficacy Study of p38 Kinase Inhibitor to Treat Patients With AtherosclerosisCompletedNCT00570752Phase 2
• Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid TumorsCompletedNCT00569036Phase 1
• Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus InfectionCompletedNCT00565539Phase 1
• CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With IrinotecanStatus unknownNCT00562419Phase 2
• A Single Ascending Dose Study of BMS-650032 in HCV Infected SubjectsCompletedNCT00559247Phase 1/2
• Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple MyelomaCompletedNCT00555100Phase 1
• A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)TerminatedNCT00550017Phase 1/2
• AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line ChemotherapyCompletedNCT00547651Phase 3
• A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First RelapseCompletedNCT00546780Phase 3
• A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)TerminatedNCT00546247Phase 1/2
• MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin LymphomaTerminatedNCT00543582Phase 2
• A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced CancerWithdrawnNCT00534807Phase 1
• ABI-008 Trial in Patients With Metastatic Breast CancerTerminatedNCT00531271Phase 1/2
• Pravastatin Efficacy and Safety Trial in Hypercholesterolemic Patients With Chronic Liver DiseaseCompletedNCT00529178Phase 4
• Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous LeukemiaCompletedNCT00528983Phase 1
• DDI HV (ATV - Merck)CompletedNCT00518297Phase 1
• Phase I Study of BMS-690514 in Japanese Patients With Solid TumorsCompletedNCT00516451Phase 1
• A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple MyelomaCompletedNCT00514371Phase 2/3
• Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer TumorsTerminatedNCT00511576Phase 1
• Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 DiabetesCompletedNCT00508287Phase 1
• Compassionate Use Trial for Unresectable Melanoma With IpilimumabNo longer availableNCT00495066
• Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety DisorderCompletedNCT00481325Phase 2/3
• AVIDA The Vidaza® (Azacitidine) Patient RegistryCompletedNCT00481273
• Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOXCompletedNCT00479583Phase 1
• ABI-008 Trial in Patients With Hormone-refractory Prostate CancerCompletedNCT00477529Phase 1/2
• A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)TerminatedNCT00461110Phase 1
• A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy SubjectsCompletedNCT00460954
• A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic SyndromesTerminatedNCT00458159Phase 1
• Expanded Access for DasatinibNo longer availableNCT00454753
• Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple MyelomaCompletedNCT00452569Phase 3
• A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's DiseaseCompletedNCT00446433Phase 2
• A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)CompletedNCT00437437Phase 1
• A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver DysfunctionCompletedNCT00437424Phase 1
• A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)CompletedNCT00435669Phase 1
• A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic LeukemiaCompletedNCT00431873Phase 2
• A Phase I Study of BMS-690514 in Combination With Paclitaxel and CarboplatinCompletedNCT00420186Phase 1
• A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic LeukemiaCompletedNCT00419250Phase 1
• ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CarcinomaTerminatedNCT00407407Phase 1
• A Study of BMS-582949 in Patients With Moderate to Severe Plaque PsoriasisCompletedNCT00399906Phase 2
• Drug Interaction - Oral ContraceptiveCompletedNCT00399685Phase 1
• A Study of BMS-562086 in Patients With Irritable Bowel SyndromeCompletedNCT00399438Phase 2
• A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected SubjectsWithdrawnNCT00397566Phase 2
• Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory LymphomaCompletedNCT00396864Phase 1
• Bioequivalence Study of Atazanavir 300 mg CapsuleCompletedNCT00393328Phase 1
• A Study of BMS-582664 in Patients With Advanced or Metastatic Solid TumorsCompletedNCT00390936Phase 1
• Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell CarcinomaCompletedNCT00389285Phase 1/2
• First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based TherapyCompletedNCT00389155Phase 2/3
• Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung CancerCompletedNCT00388960Phase 2
• Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese SubjectsTerminatedNCT00388609Phase 2
• Effect of Ketoconazole on the Pharmacokinetics of VinflunineCompletedNCT00388557Phase 1
• Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected PatientsCompletedNCT00384904Phase 4
• A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study DrugCompletedNCT00382668
• Pravastatin or Atorvastatin Evaluation and Infection Therapy (TIMI22)CompletedNCT00382460Phase 4
• Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast CancerWithdrawnNCT00380835Phase 2
• Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior TherapyCompletedNCT00375193Phase 2
• MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory DiseaseTerminatedNCT00374296Phase 2
• CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's LymphomaCompletedNCT00374179Phase 1
• A Phase I/II Study of MGCD0103 (MG-0103) in Combination With GemcitabineCompletedNCT00372437Phase 1/2
• Study of Recombinant Human Thrombin for Bleeding During Autologous Skin GraftingCompletedNCT00371215Phase 2
• Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/TenofovirCompletedNCT00365339Phase 1
• A Study of the Alternative Administration of Ixabepilone and VinflunineCompletedNCT00362830Phase 1
• Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate RosiglitazoneCompletedNCT00362726Phase 1
• Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical ResectionCompletedNCT00362713Phase 1
• A Study of Vinflunine in Patients With Gastric CancerTerminatedNCT00359476Phase 2/3
• Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)TerminatedNCT00359450Phase 2
• Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory LymphomaCompletedNCT00359086Phase 2
• Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's LymphomaTerminatedNCT00358982Phase 2
• Atazanavir Twice DailyCompletedNCT00357721Phase 1
• Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy FemalesCompletedNCT00357604Phase 1
• Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV MelanomaWithdrawnNCT00357461Phase 2
• Drug Interaction Study With Proton Pump InhibitorCompletedNCT00357240Phase 1
• Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy SubjectsCompletedNCT00357188Phase 1
• Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)CompletedNCT00352560Phase 3

← Bristol-Myers Squibb overview and focus areas